About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer

NCT07121387·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Shanghai Pulmonary Hospital, Shanghai, China

Age

Any age

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Diagnosed with stage III-IV NSCLC according to the American Joint Committee on Cancer staging criteria (7th edition);
Lesions are measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;
Receiving first-line immunotherapy or chemotherapy as anti-tumor treatment.

You may not be if

SMARCA4 gene test was not performed;
Not receive treatment;
Lost to follow-up after one treatment cycle.

The record

StatusCompleted

PhaseNo phase

Taking part221

StartedJan 2020

UpdatedAug 13, 2025

Conditions

SMARCA4-Deficient Tumor NSCLC (Advanced Non-small Cell Lung Cancer)

Where1

Shanghai Pulmonary Hospital
Shanghai, China

Clareo Health | A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer